UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Journal of clinical oncology, 2020-11, Vol.38 (31), p.3592-3603

2020

Volltextzugriff (PDF)

Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

Journal of thoracic oncology, 2021-12, Vol.16 (12), p.2091-2108

2021

Volltextzugriff (PDF)

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Journal of thoracic oncology, 2020-03, Vol.15 (3), p.404-415

2020

Volltextzugriff (PDF)

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis

Pharmaceuticals (Basel, Switzerland), 2020-11, Vol.13 (11), p.371

2020

Volltextzugriff (PDF)

Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability

BMC proceedings, 2024-01, Vol.18 (Suppl 3), p.2-2, Article 2

2024

Volltextzugriff (PDF)

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

Journal of clinical oncology, 2023-04, Vol.41 (11), p.1992-1998

2023

Volltextzugriff (PDF)

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2020-05, Vol.38 (14), p.1505-1517

2020

Volltextzugriff (PDF)

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

The New England journal of medicine, 2018-05, Vol.378 (22), p.2078-2092

2018

Volltextzugriff (PDF)

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

The New England journal of medicine, 2018-12, Vol.379 (23), p.2220-2229

2018

Volltextzugriff (PDF)

Plain language summary of the final results from the GioTag study

Future oncology (London, England), 2021-09, Vol.17 (25), p.3285-3290

Hochmair, Maximilian J

2021

Volltextzugriff (PDF)

Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients

Biomolecules (Basel, Switzerland), 2021-04, Vol.11 (5), p.618

2021

Volltextzugriff (PDF)

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report

JTO clinical and research reports, 2022-06, Vol.3 (6), p.100330-100330, Article 100330

2022

Volltextzugriff (PDF)

Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients

Clinical Medicine Insights. Oncology, 2021, Vol.15, p.1179554921993072-1179554921993072

2021

Volltextzugriff (PDF)

Overcoming resistance in small-cell lung cancer

Expert review of respiratory medicine, 2024-08, Vol.18 (8), p.569-580

2024

Volltextzugriff (PDF)

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

Journal of clinical oncology, 2017-08, Vol.35 (22), p.2490-2498

2017

Volltextzugriff (PDF)

How can better identification of T790M help to inform treatment sequencing decisions in EGFR mutation-positive non-small-cell lung cancer?

Future oncology (London, England), 2019-09, Vol.15 (25), p.2895-2898

Hochmair, Maximilian J

2019

Volltextzugriff (PDF)

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

JTO clinical and research reports, 2022-09, Vol.3 (9), p.100385-100385, Article 100385

2022

Volltextzugriff (PDF)

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib

Targeted oncology, 2019-02, Vol.14 (1), p.75-83

2019

Volltextzugriff (PDF)

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials

Journal of clinical oncology, 2018-09, Vol.36 (26), p.2693-2701

2018

Volltextzugriff (PDF)

Complete remission of intrathecal metastases with lorlatinib therapy in a heavily pretreated ALK-positive lung cancer patient

Anti-cancer drugs, 2017-09, Vol.28 (8), p.928-930

2017

Volltextzugriff (PDF)

Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy

Lung cancer (Amsterdam, Netherlands), 2017-11, Vol.113, p.4-6

2017

Volltextzugriff (PDF)

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study

Future oncology (London, England), 2020-12, Vol.16 (34), p.2799-2808

2020

Volltextzugriff (PDF)

Prognostic significance of circulating tumor cells and tumor related transcripts in small cell lung cancer: A step further to clinical implementation

International journal of cancer, 2024-06, Vol.154 (12), p.2189-2199

2024

Volltextzugriff (PDF)

Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)

Lung cancer (Amsterdam, Netherlands), 2021-12, Vol.162, p.9-15

2021

Volltextzugriff (PDF)

1 – 25 von 94

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(90)
Mit Volltextzugriff
(80)

Publikationsform

Artikel
(94)

Sprache

Englisch
(93)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(52)
Science & Technology
(52)
Oncology
(40)
Humans
(35)
Lung Cancer
(27)
Lung Neoplasms - Drug Therapy
(27)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(20)
Middle Aged
(20)
Mutation
(20)
Female
(19)
Lung Neoplasms - Pathology
(18)
Aged
(17)
Lung Neoplasms - Genetics
(17)
Male
(17)
Adult
(16)
Aged, 80 And Over
(15)
Metastasis
(14)
Protein Kinase Inhibitors - Therapeutic Use
(14)
Carcinoma, Non-Small-Cell Lung - Genetics
(13)
Patients
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis

Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Plain language summary of the final results from the GioTag study

Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients

Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report

Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients

Overcoming resistance in small-cell lung cancer

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

How can better identification of T790M help to inform treatment sequencing decisions in EGFR mutation-positive non-small-cell lung cancer?

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials

Complete remission of intrathecal metastases with lorlatinib therapy in a heavily pretreated ALK-positive lung cancer patient

Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study

Prognostic significance of circulating tumor cells and tumor related transcripts in small cell lung cancer: A step further to clinical implementation

Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)

Suchergebnisse filtern